T. Rowe Price Associates
AZN icon

T. Rowe Price Associates’s AstraZeneca AZN Stock Holding History

T. Rowe Price Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,750
Closed -$524K – 2981
2021
Q4 		$524K Sell
4,750
-7,000
-60% -$824K ﹤0.01% 2367
2021
Q3 		$1.41M Buy
11,750
+1,150
+11% +$134K ﹤0.01% 1875
2021
Q2 		$1.27M Buy
+10,600
New +$1.16M ﹤0.01% 1959

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates's AZN Position: Q2 2026 in Review

T. Rowe Price Associates reduced its AstraZeneca (AZN) stake by 15% in Q2 2026, selling an estimated $540M and leaving 16,616,629 shares worth $3.15B. The position accounts for 0.32% of the portfolio, ranked #60.

T. Rowe Price Associates first reported a position in AZN in Q2 2013 and has held it in 44 quarters since. The position peaked at $6.25B in Q1 2022. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • T. Rowe Price Associates held 16,616,629 shares of AstraZeneca worth $3.15B as of Q2 2026.
  • T. Rowe Price Associates sold 2,872,591 AstraZeneca shares in Q2 2026, an estimated $540M.
  • AstraZeneca made up 0.32% of T. Rowe Price Associates's portfolio in Q2 2026, its #60 holding.
  • T. Rowe Price Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 44 quarters since.
  • T. Rowe Price Associates's AstraZeneca position peaked at $6.25B in Q1 2022.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.